Impact of NAFLD and its pharmacotherapy on lipid profile and CVD

Wang, Zhenya; Ye, Mao; Zhang, Xiaojing; Zhang, Peng; Cai, Jingjing; Li, Hongliang; She, Zhi‐Gang

doi:10.1016/j.atherosclerosis.2022.07.010

Cited by 18 publications

(18 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because metabolic syndrome is related to NAFLD, abnormal lipid metabolism is common in individuals with NAFLD and can increase the risk of CVD (115)(116)(117). Therefore, lipid-lowering strategies are critical for individuals with NAFLD.…”

Section: Statinsmentioning

confidence: 99%

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Yang

Tian²,

Zhang³

et al. 2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

In the past few decades, non-alcoholic fatty liver disease (NAFLD) and heart failure with preserved ejection fraction (HFpEF) have become the most common chronic liver disease and the main form of heart failure (HF), respectively. NAFLD is closely associated with HFpEF by sharing common risk factors and/or by boosting systemic inflammation, releasing other secretory factors, and having an expansion of epicardial adipose tissue (EAT). Therefore, the treatments of NAFLD may also affect the development and prognosis of HFpEF. However, no specific drugs for NAFLD have been approved by the Food and Drug Administration (FDA) and some non-specific treatments for NAFLD are applied in the clinic. Currently, the treatments of NAFLD can be divided into non-pharmacological and pharmacological treatments. Non-pharmacological treatments mainly include dietary intervention, weight loss by exercise, caloric restriction, and bariatric surgery. Pharmacological treatments mainly include administering statins, thiazolidinediones, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and metformin. This review will mainly focus on analyzing how these treatments may affect the development and prognosis of HFpEF.

show abstract

Section: Statinsmentioning

confidence: 99%

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Yang

Tian²,

Zhang³

et al. 2023

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, NAFLD is linked to changes in lipid metabolism that may have a direct role in the onset of atherosclerosis. Thus, triacylglycerol (TG) and LDL, known risk factors for atherosclerosis, are elevated in individuals with NAFLD, which is often also associated with reduced levels of the protective high-density lipoprotein (HDL) [31].…”

Section: Risk Factors For Atherosclerosismentioning

confidence: 99%

The Role of Punicalagin and Its Metabolites in Atherosclerosis and Risk Factors Associated with the Disease

Alalawi,

Albalawi,

Ramji

2023

IJMS

View full text Add to dashboard Cite

Atherosclerotic cardiovascular disease (ACVD) is the leading cause of death worldwide. Although current therapies, such as statins, have led to a marked reduction in morbidity and mortality from ACVD, they are associated with considerable residual risk for the disease together with various adverse side effects. Natural compounds are generally well-tolerated; a major recent goal has been to harness their full potential in the prevention and treatment of ACVD, either alone or together with existing pharmacotherapies. Punicalagin (PC) is the main polyphenol present in pomegranates and pomegranate juice and demonstrates many beneficial actions, including anti-inflammatory, antioxidant, and anti-atherogenic properties. The objective of this review is to inform on our current understanding of the pathogenesis of ACVD and the potential mechanisms underlying the beneficial actions of PC and its metabolites in the disease, including the attenuation of dyslipidemia, oxidative stress, endothelial cell dysfunction, foam cell formation, and inflammation mediated by cytokines and immune cells together with the regulation of proliferation and migration of vascular smooth muscle cells. Some of the anti-inflammatory and antioxidant properties of PC and its metabolites are due to their strong radical-scavenging activities. PC and its metabolites also inhibit the risk factors of atherosclerosis, including hyperlipidemia, diabetes mellitus, inflammation, hypertension, obesity, and non-alcoholic fatty liver disease. Despite the promising findings that have emerged from numerous in vitro, in vivo, and clinical studies, deeper mechanistic insights and large clinical trials are required to harness the full potential of PC and its metabolites in the prevention and treatment of ACVD.

show abstract

“…Over the past decade, it has become increasingly clear that MAFLD is strongly associated with increased risk of CVDs, which are the leading cause of death among MAFLD patients. 15 …”

Section: Introductionmentioning

confidence: 99%

Genetic and Lifestyle Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Relationship with Premature Coronary Artery Disease: A Study on the Pars Cohort

Anushiravani,

rayatpisheh,

Kasaeian

et al. 2024

Arch Iran Med

View full text Add to dashboard Cite

Background: The main objective of this study is to identify the risk factors of metabolic dysfunction-associated fatty liver disease (MAFLD) in coronary artery disease (CAD) patients. Methods: The present retrospective cohort study is part of the Pars Cohort Study (PCS). The participants were categorized as having MAFLD or not. The pattern of independent variables in patients was compared with those who did not have MAFLD. All variables were retained in the multivariable logistic regression model. Results: Totally, 1862 participants with CAD were enrolled in this study. MAFLD was diagnosed in 647 (40.1%) participants. Gender, diabetes, hypertension, tobacco, opium, alcohol, age, weight, waist circumference, cholesterol, HDL, triglyceride, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were significantly different in MAFLD and non-MAFLD patients. Also, the results of multivariable logistic regression show male gender (OR=0.651, 95% CI: 0.470‒0.902, P value=0.01) and opium consumption (OR=0.563, 95% CI: 0.328‒0.968, P value<0.001) to be negative risk factors of MAFLD occurrence in CAD patients. Having diabetes (OR=2.414, 95% CI: 1.740-3.349, P value<0.001), high waist circumference (OR=1.078, 95% CI: 1.055‒1.102, P value<0.01), high triglyceride (OR=1.005, 95% CI: 1.001‒1.008, P value=0.006), and high ALT (OR=1.039, 95% CI: 1.026‒1.051, P value<0.01) were positive risk factors of MAFLD in CAD patients. Conclusion: Our study found that consuming opium decreases the likelihood of MAFLD in CAD patients, since these patients have decreased appetite and lower body mass index (BMI). On the other hand, female gender, having diabetes, high waist circumference, high triglyceride levels, and high ALT levels increase the probability of MAFLD in CAD patients.

show abstract

Impact of NAFLD and its pharmacotherapy on lipid profile and CVD

Cited by 18 publications

References 158 publications

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction

The Role of Punicalagin and Its Metabolites in Atherosclerosis and Risk Factors Associated with the Disease

Genetic and Lifestyle Risk Factors of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Relationship with Premature Coronary Artery Disease: A Study on the Pars Cohort

Contact Info

Product

Resources

About